Abstract：
Glucagon-like peptide 1 (GLP-1) analogs regulate body weight and liver steatosis. Different body adipose tissue (AT) depots exhibit biological variability. Accordingly, GLP-1 analog effects on AT distribution are unclear.
To investigate GLP1-analog effects on adiposity distribution.
PubMed, Cochrane, and Scopus databases were screened for eligible randomized human trials. Pre-defined endpoints included visceral AT (VAT), subcutaneous AT (SAT), total AT (TAT), epicardial AT (EAT), liver AT (LAT), and waist-to-hip ratio (W:H). Search was conducted until May 17, 2022.
Data extraction and bias assessment were performed by two independent investigators. Treatment effects were estimated using random effects models. Analyses were performed on Review Manager v5.3.
Out of the 367 screened studies, 45 were included in the systematic review and 35 were used in the meta-analysis. GLP-1 analogs reduced VAT, SAT, TAT, LAT, and EAT, with non-significant effects on W:H. Overall bias risk was low.
GLP-1 analog treatment reduces TAT, affecting most studied AT depots, including the pathogenic VAT, EAT, and LAT. GLP-1 analogs may have significant roles in combating metabolic, obesity-associated diseases via reductions of key AT depot volumes.
To investigate GLP1-analog effects on adiposity distribution.
PubMed, Cochrane, and Scopus databases were screened for eligible randomized human trials. Pre-defined endpoints included visceral AT (VAT), subcutaneous AT (SAT), total AT (TAT), epicardial AT (EAT), liver AT (LAT), and waist-to-hip ratio (W:H). Search was conducted until May 17, 2022.
Data extraction and bias assessment were performed by two independent investigators. Treatment effects were estimated using random effects models. Analyses were performed on Review Manager v5.3.
Out of the 367 screened studies, 45 were included in the systematic review and 35 were used in the meta-analysis. GLP-1 analogs reduced VAT, SAT, TAT, LAT, and EAT, with non-significant effects on W:H. Overall bias risk was low.
GLP-1 analog treatment reduces TAT, affecting most studied AT depots, including the pathogenic VAT, EAT, and LAT. GLP-1 analogs may have significant roles in combating metabolic, obesity-associated diseases via reductions of key AT depot volumes.
摘要：
背景：胰高血糖素样肽1（GLP-1）类似物调节体重和肝脏脂肪变性。不同的身体脂肪组织(AT)储库表现出生物变异性。因此，GLP-1类似物对AT分布的影响尚不清楚。
目的：研究GLP1类似物对肥胖分布的影响。
方法：PubMed，科克伦,和Scopus数据库被筛选为符合条件的随机人体试验。预定义的终点包括内脏AT（VAT），皮下AT（SAT），总AT(TAT)，心外膜AT(EAT),肝脏AT(LAT),腰臀比（W：H）。搜索一直持续到2022年5月17日。
方法：由两名独立研究者进行数据提取和偏倚评估。使用随机效应模型估计治疗效果。在ReviewManagerv5.3上进行了分析。
结果：在367项筛选研究中，45例纳入系统评价，35例纳入荟萃分析。GLP-1类似物降低增值税，SAT,TAT,LAT,吃,对W:H无显著影响总体偏倚风险较低。
结论：GLP-1类似物治疗可降低TAT，影响大多数研究过的AT仓库，包括致病性增值税，EAT,和LAT。GLP-1类似物可能在对抗代谢，通过减少关键AT仓库的数量与肥胖相关的疾病。
目的：研究GLP1类似物对肥胖分布的影响。
方法：PubMed，科克伦,和Scopus数据库被筛选为符合条件的随机人体试验。预定义的终点包括内脏AT（VAT），皮下AT（SAT），总AT(TAT)，心外膜AT(EAT),肝脏AT(LAT),腰臀比（W：H）。搜索一直持续到2022年5月17日。
方法：由两名独立研究者进行数据提取和偏倚评估。使用随机效应模型估计治疗效果。在ReviewManagerv5.3上进行了分析。
结果：在367项筛选研究中，45例纳入系统评价，35例纳入荟萃分析。GLP-1类似物降低增值税，SAT,TAT,LAT,吃,对W:H无显著影响总体偏倚风险较低。
结论：GLP-1类似物治疗可降低TAT，影响大多数研究过的AT仓库，包括致病性增值税，EAT,和LAT。GLP-1类似物可能在对抗代谢，通过减少关键AT仓库的数量与肥胖相关的疾病。
